An article in today’s Daily Telegraph in the UK starts with the misleading statement that, “Up to half of men diagnosed with prostate cancer are being given ‘false hope’ by tests that are underestimating the severity of their disease, according to the authors of a new study.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, Diagnosis, expectant management, media, naivety, risk | 8 Comments »
Three papers published on line in the Journal of Urology last week have meaningful implications for greater standardization of the ways physicians need to make decisions about the appropriate identification, selection, and management of candidates for active surveillance as compared to immediate therapy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, biopsy, expectant management, quality of care, survival | 2 Comments »
Many readers may be interested in an article on active surveillance and other forms of expectant management by Khurana and Stephenson that appears on the front page of the November issue of the AUA News. This article is based on a poster presented by Khurana et al. at the annual meeting of the American Urological Association earlier this year.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, expectant management, observation, watchful waiting | 1 Comment »
On January 1 this year we offered a short list of just three “major” trials that we were hoping to see results from in 2011. One of these trials was the randomized, U.S.-based trial of “palliative expectant management” vs. radical surgery in men with localized prostate cancer (the Prostate Cancer Intervention Versus Observation Trial or PIVOT). … READ MORE …
Filed under: Management, Treatment | Tagged: expectant management, PIVOT, radical prostatectomy | Leave a comment »
It has been hoped (at least by some) that a possible use of the prostate cancer gene 3 or PCA3 test — approved in parts of Europe but still in clinical trials in the US — would be as a better tool than PSA tests and annual biopsies to monitor patients on expectant management (active surveillance). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, expectant management, PCA3, progression | 11 Comments »
Yet another study has added to the available data on the potential of conservative management for newly diagnosed prostate cancer patients. The current study reflects experience most specifically with the management of men of ≥ 65 years of age. … READ MORE …
Filed under: Management, Treatment | Tagged: conservative, expectant management, outcomes | 4 Comments »
Many readers might be interesting in listening to (or reading the transcript of) a discussion between Ira Flatow of National Public Radio and Dr. Martin Sanda of Harvard University that was broadcast on the program “Science Friday” on September 4th. … READ MORE …
Filed under: Diagnosis, Management, Risk, Uncategorized | Tagged: active surveillance, Diagnosis, expectant management, risk, watchful waiting | Leave a comment »
An article by Linda Beck in the Health Matters section of the Wall Street Journal today weighs in on the pros and cons of “watchful waiting” as a management strategy that is increasingly considered appropriate for many men with low risk, early stage prostate cancer. … READ MORE …
Filed under: Management | Tagged: active surveillance, expectant management, watchful waiting | 8 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 